Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP)

Pulmonary Fibrosis ◽

Acute Exacerbation ◽

Study Protocol ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Effects of acetyl-DL-leucine on cerebellar ataxia (ALCAT trial): study protocol for a multicenter, multinational, randomized, double-blind, placebo-controlled, crossover phase III trial

BMC Neurology ◽

10.1186/s12883-016-0786-x ◽

2017 ◽

Vol 17 (1) ◽

Cited By ~ 14

Author(s):

Katharina Feil ◽

Christine Adrion ◽

Julian Teufel ◽

Sylvia Bösch ◽

Jens Claassen ◽

...

Keyword(s):

Cerebellar Ataxia ◽

Study Protocol ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Crossover Phase

The CAPACITY (CAP) Trials: Randomized, Double-Blind, Placebo-Controlled, Phase III Trials of Pirfenidone (PFD) in Patients with Idiopathic Pulmonary Fibrosis (IPF).

10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a1129 ◽

2009 ◽

Cited By ~ 2

Author(s):

P Noble ◽

C Albera ◽

W Bradford ◽

U Costabel ◽

D Kardatzke ◽

...

Keyword(s):

Pulmonary Fibrosis ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Trials

Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(21)00354-4 ◽

2021 ◽

Author(s):

Jean-Marc Naccache ◽

Stéphane Jouneau ◽

Morgane Didier ◽

Raphaël Borie ◽

Marine Cachanado ◽

...

Keyword(s):

Pulmonary Fibrosis ◽

Acute Exacerbation ◽

Phase 3 ◽

Double Blind ◽

CryptoDex: A randomised, double-blind, placebo-controlled phase III trial of adjunctive dexamethasone in HIV-infected adults with cryptococcal meningitis: study protocol for a randomised control trial

Trials ◽

10.1186/1745-6215-15-441 ◽

2014 ◽

Vol 15 (1) ◽

Cited By ~ 15

Author(s):

Jeremy Day ◽

Darma Imran ◽

Ahmed Rizal Ganiem ◽

Natriana Tjahjani ◽

Retno Wahyuningsih ◽

...

Keyword(s):

Study Protocol ◽

Cryptococcal Meningitis ◽

Phase Iii ◽

Randomised Control Trial ◽

Double Blind ◽

Phase Iii Trial ◽

RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial

10.1183/13993003.congress-2021.rct2903 ◽

2021 ◽

Author(s):

Jean-Marc Naccache ◽

Stephane Jouneau ◽

Morgane Didier ◽

Raphaël Borie ◽

Marine Cachanado ◽

...

Keyword(s):

Pulmonary Fibrosis ◽

Acute Exacerbation ◽

Phase 3 ◽

Double Blind ◽

Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial

American Journal of Respiratory and Critical Care Medicine ◽

10.1164/rccm.201909-1818oc ◽

2020 ◽

Vol 201 (9) ◽

pp. 1110-1119 ◽

Cited By ~ 9

Author(s):

Yasuhiro Kondoh ◽

Arata Azuma ◽

Yoshikazu Inoue ◽

Takashi Ogura ◽

Susumu Sakamoto ◽

...

Keyword(s):

Pulmonary Fibrosis ◽

Acute Exacerbation ◽

Controlled Trial ◽

Double Blind ◽

Faculty Opinions recommendation of Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1146988.604098 ◽

2009 ◽

Author(s):

Frank Pessler

Keyword(s):

Juvenile Idiopathic Arthritis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Withdrawal Phase ◽

Systemic Onset

Faculty Opinions recommendation of Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717996902.793477633 ◽

2013 ◽

Author(s):

Virginia Kraus

Keyword(s):

Hip Pain ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Pamrevlumab (FG-3019), an Anti-Connective Tissue Growth Factor Therapy for Idiopathic Pulmonary Fibrosis: A Randomized, Double-Blind, Placebo-Controlled Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3379814 ◽

2019 ◽

Author(s):

Luca Richeldi ◽

Evans R. Fernández Pérez ◽

Ulrich Costabel ◽

Carlo Albera ◽

David J. Lederer ◽

...

Keyword(s):

Growth Factor ◽

Connective Tissue ◽

Pulmonary Fibrosis ◽

Controlled Trial ◽

Tissue Growth ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Therapy ◽

Growth Factor Therapy

Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara®) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial

Contraception ◽

10.1016/j.contraception.2009.02.016 ◽

2009 ◽

Vol 80 (1) ◽

pp. 25-33 ◽

Cited By ~ 27

Author(s):

Gerd Plewig ◽

William J. Cunliffe ◽

Natascha Binder ◽

Kornelia Höschen

Keyword(s):

Oral Contraceptive ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽